Acute Lymphoblastic Leukemia in the Older Adult
Authors:
- 1 February 2019
- journal article
- editorial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Oncology Practice
- Vol. 15 (2) , 67-75
Abstract
Acute lymphoblastic leukemia (ALL) in older adults presents a real challenge as a result of adverse disease biology and comorbidities that preclude delivering curative regimens. Conventional chemotherapy approaches have generally yielded unsatisfactory results in older patients with ALL as a result of excessive induction mortality, chemotherapy resistance of the leukemia, and the need to omit or dose reduce key drugs during the course of therapy because of adverse effects. Philadelphia chromosome–positive ALL represents about a quarter of newly diagnosed older adults, and the striking single-agent activity and excellent safety profile of tyrosine kinase inhibitors has allowed incorporation of these agents into therapy, significantly improving the outcome of older adults with Philadelphia chromosome–positive ALL. Allogeneic hematopoietic cell transplantation using reduced-intensity conditioning is a potentially curative approach in the older adult with ALL, and ironically, it may be better tolerated than intensive combination chemotherapy in a subset of older patients with ALL. Immunotherapies such as chimeric antigen receptor–modified T-cells, the bispecific T-cell–engaging antibody targeting CD19 (blinatumomab), and the antibody-drug conjugate targeting CD22 (inotuzumab) have shown safety and exceptional activity even in advanced ALL, and the efficacy of these agents has been observed irrespective of patient age. Several promising studies tailored specifically toward older adults with ALL are ongoing, with the majority of them incorporating novel immunotherapies, targeted therapies, or third-generation tyrosine kinase inhibitors into the front-line treatment regimen.Keywords
This publication has 46 references indexed in Scilit:
- TP53 mutations occur in 15.7% of ALL and are associated with MYC-rearrangement, low hypodiploidy, and a poor prognosisBlood, 2014
- A Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive LeukemiasNew England Journal of Medicine, 2013
- Clinico-biological features of 5202 patients with acute lymphoblastic leukemia enrolled in the Italian AIEOP and GIMEMA protocols and stratified in age cohortsHaematologica, 2013
- Outcomes in older adults with acute lymphoblastic leukaemia (ALL): results from the international MRC UKALL XII/ECOG2993 trialBritish Journal of Haematology, 2012
- Dasatinib as first-line treatment for adult patients with Philadelphia chromosome–positive acute lymphoblastic leukemiaBlood, 2011
- A randomized study of pegylated liposomal doxorubicin versus continuous-infusion doxorubicin in elderly patients with acute lymphoblastic leukemia: the GRAALL-SA1 studyHaematologica, 2010
- A population-based cytogenetic study of adults with acute lymphoblastic leukemiaBlood, 2010
- Results of the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen in elderly patients with acute lymphocytic leukemiaCancer, 2008
- Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosome–positive patients with acute lymphoblastic leukemia without additional chemotherapy: results of the Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) LAL0201-B protocolBlood, 2007
- Results of the PETHEMA ALL‐96 trial in elderly patients with Philadelphia chromosome‐negative acute lymphoblastic leukemiaEuropean Journal of Haematology, 2006